Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Cisco Systems

MGM Resorts

Wall Street investors are looking for cheap stocks to buy before the summer holiday period. Despite the rally we have witnessed so far in the year, risks like increased market volatility and uncertainty over economic factors still persist.

Bargain Bin: 3 Cheap Stocks to Buy Before Memorial Day

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Merck (MRK) is a Top Momentum Stock for the Long-Term

Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.

Here's Why Merck (MRK) Stock Has Outperformed Industry YTD

Amazon

American Express

SPDR Dow Jones Industrial Average ETF

Goldman Sachs

Walmart

The Dow Jones touched the milestone of 40,000 for the first time on strong corporate earnings and renewed bets for rate cuts. We have highlighted five ETFs that have been leading the way higher this year.

5 Stocks Powering the Dow ETF Year to Date

Costco

Dominion Energy

Home Depot

T-Mobile US

YUM! Brands

With the market potentially entering a period of consolidation, investors may want to consider safe haven stocks to buy. No, it's not the most exciting idea.

Storm Shelter: 7 Safe Haven Stocks to Batten Down the Hatches

Apple

Caterpillar

Chevron

JPMorgan Chase & Co

Microsoft

Travelers

UnitedHealth Group

CNBC's Jim Cramer listed ten stocks that helped the Dow Jones Industrial Average briefly top 40,000 on Thursday, a new high for the index.

Cramer says these 10 stocks helped the Dow briefly crack 40,000

Eli Lilly

Novo Nordisk

Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.

3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance

Merck (MRK) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MRK broke through the 20-day moving average, which suggests a short-term bullish trend.

Merck (MRK) Crossed Above the 20-Day Moving Average: What That Means for Investors

Merck & Co., Inc. (NYSE:MRK ) BofA Securities 2024 Health Care Conference May 15, 2024 4:40 PM ET Company Participants Caroline Litchfield - EVP & CFO Conference Call Participants Geoff Meacham - Bank of America Securities Geoff Meacham [Call Starts abruptly] Caroline Litchfield, CFO. Caroline, good to see you.

Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript)

AbbVie

Ally Financial

Comcast

Camden Property

Discover

DHL Group

Dow Inc

Elevance Health Inc

First American Financial

MetLife

Nucor

Teleperformance

The April/May 2024 edition of Fortune Magazine revealed its 100 Best Companies To Work For, or Besties. My latest Dogcatcher-quest to sniff-out the best dividend-buys found 56 dividend-paying Besties using YCharts 5/13/24 data.

2 Fortune 100 Best Co's To Work For Are Also Good To Own

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline.

Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline

Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.

Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility

Merck said on Monday it had discontinued the arm of a late-stage study, which tested an experimental antibody-based drug with its blockbuster immunotherapy Keytruda for some patients with the most severe form of skin cancer.

Merck stops skin cancer combination therapy testing in late-stage study

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma.

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma

Coca-Cola

W. P. Carey

Xcel Energy

5 companies in Rose's Income Garden portfolio gave April raises, spanning different sectors including consumer staples, healthcare, utility, technology, and real estate. The raises varied in percentage, with some exceeding expectations and others being more modest. The article provides an analysis of each company's dividend growth rate, payout ratio, credit rating, and other relevant statistics, along with my take and recommendation for each stock.

5 April Quality Dividend Growth Stock Raises

Abbott Labs

Bank of America

Honeywell

If you want your portfolio to pay you cash like clockwork, it's time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.

JP Morgan Has 5 Blue Chip Passive Income Stocks as Top Picks for May

On April 25, one of the leaders in the global oncology drugs market published extremely positive financial results for the first quarter of 2024. Keytruda sales were about $6.95 billion in the first quarter of 2024, up 19.9% year-over-year. Additionally, Gardasil/Gardasil 9 sales totaled about $2.25 billion in the first three months of 2024, up 14% year over year.

Merck: The Worst Has Been Avoided (Rating Upgrade)

Pfizer

Teladoc

A commonly used strategy for investing is sector rotation. This involves the movement of funds from one sector to another based on macroeconomic and other factors.

The 3 Most Undervalued Healthcare Stocks to Buy in May 2024

Altimmune

Amgen

AstraZeneca

Structure Therapeutics Inc

Viking Therapeutics

Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ).

7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025

Merck said on Thursday its treatment for a type of uterus cancer did not meet the main goal of disease-free survival in a late-stage trial.

Merck treatment for a type of uterus cancer fails trial

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial.

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Bank of America Securities 2024 Healthcare Conference.

Merck to Participate in the Bank of America Securities 2024 Healthcare Conference

NVIDIA

Dow Jones drug giant Merck and Nvidia stock are among the best stocks to buy and watch in today's stock market action.

Dow Jones Drug Giant Merck, Nvidia Eye Buy Points In Current Stock Market

PRESS RELEASE - 06/05/2024, 07:00 CEST Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region Biocartis (Mechelen, Belgium) announced an expansion of its collaboration with Merck Serono Middle East and Merck Saudi Ltd., both affiliates of Merck KGaA (“Merck”).

Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region

News for Merck Stock (MRK)